Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 18, 2017 - Issue 10
Submit an article Journal homepage
1,016
Views
6
CrossRef citations to date
0
Altmetric
Editorial

How far away from having an effective treatment option for progressive multiple sclerosis are we?

Arianna SartoriDepartment of Medical, Surgical, and Health Sciences, University of Trieste, Azienda Sanitaria Universitaria Integrata di Trieste, Neurology Unit – Cattinara Hospital, Trieste, ItalyCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-4518-518XView further author information
ORCID Icon,
Jacopo FantiniDepartment of Medical, Surgical, and Health Sciences, University of Trieste, Azienda Sanitaria Universitaria Integrata di Trieste, Neurology Unit – Cattinara Hospital, Trieste, ItalyORCID Iconhttp://orcid.org/0000-0002-6951-8049View further author information
ORCID Icon &
Paolo ManganottiDepartment of Medical, Surgical, and Health Sciences, University of Trieste, Azienda Sanitaria Universitaria Integrata di Trieste, Neurology Unit – Cattinara Hospital, Trieste, ItalyORCID Iconhttp://orcid.org/0000-0001-5305-6268View further author information
ORCID Icon
Pages 953-955 | Received 18 Mar 2017, Accepted 02 May 2017, Published online: 16 May 2017

References

  • Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14:183–193.
  • Ontaneda D, Thompson AJ, Fox RJ, et al. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet. 2016. published online 23 November 2016. doi:10.1016/s0140-6736(16)31320-4.
  • Shirani A, Okuda DT, Stüve O. Therapeutic advances and future prospects in progressive forms of multiple sclerosis. Neurotherapeutics. 2016;13:58–69.
  • Hartung HP, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360:2018–2025.
  • Martinelli Boneschi F, Vacchi L, Rovaris M, et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013;(5):CD002127. doi:10.1002/14651858.CD002127.pub3.
  • European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352:1491–1497.
  • Kuhle J, Hardmeier M, Disanto G, et al. A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis. Mult Scler. 2016;22:533–543.
  • Wolinsky JS, Narayana PA, O’Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007;61:14–24.
  • Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1075–1084.
  • Freedman MS, Bar-Or A, Oger J, et al. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology. 2011;77:1551–1560.
  • Steiner D, Arnold D, Freedman M, et al. Natalizumab versus placebo in patients with secondary progressive multiple sclerosis (SPMS): results from ASCEND, a multicenter, double-blind, placebo-controlled, randomized phase 3 clinical trial. Neurology. 2016;86(16Supplement):abstr. ES1.009.
  • Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis. Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66:460–471.
  • Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209–220.
  • Kappos L, Bar-Or A, Cree B, et al. Efficacy and safety of siponimod in secondary progressive multiple sclerosis – results of the placebo controlled, double-blind, phase III EXPAND study. Mult Scler. 2016;22(S3):828–883,abstr. 250.
  • Tourbah A, Lebrun-Frenay C, Edan G, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study. Mult Scler. 2016;22:1719–1731.
  • Zajicek J, Ball S, Wright D, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol. 2013;12:857–865.
  • Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015;14:208–223.
  • Spain R, Murchison C, Horak F, et al. Lipoic acid for neuroprotection in secondary progressive multiple sclerosis. Neurology. 2016;86(16Supplement):abstr. P1.373.
  • Cadavid D, Edwards KR, Hupperts R, et al. Efficacy analysis of opicinumab in relapsing multiple sclerosis: the phase 2b SYNERGY trial. Mult Scler. 2016;22(S3):66,abstr. 192.
  • Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–286.
  • Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–234.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.